B-LYMPHOCYTE ANTIGEN CD19

Investigational

Approval Year

Substance Class	Protein Created by `admin` on `Tue Apr 01 20:06:21 GMT 2025` Edited by `admin` on `Tue Apr 01 20:06:21 GMT 2025`
Protein Sub Type
Sequence Type	COMPLETE
Record UNII	IYZ9TI08W3
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

B-LYMPHOCYTE SURFACE ANTIGEN B4

Preferred Name

English

B-LYMPHOCYTE ANTIGEN CD19

Common Name

English

CD19

Common Name

English

CD-19

Common Name

English

T-CELL SURFACE ANTIGEN LEU-12

Common Name

English

DIFFERENTIATION ANTIGEN CD19

Common Name

English

Code System Code Type Description

FDA UNII

IYZ9TI08W3

Created by admin on Tue Apr 01 20:06:21 GMT 2025 , Edited by admin on Tue Apr 01 20:06:21 GMT 2025

PRIMARY

UNIPROT

P15391

Created by admin on Tue Apr 01 20:06:21 GMT 2025 , Edited by admin on Tue Apr 01 20:06:21 GMT 2025

PRIMARY

From	To
1_19	1_78
1_181	1_242

Glycosylation Type

HUMAN

Glycosylation Link Type	Site
N	1_67
N	1_106
N	1_119
N	1_162
N	1_246

Related Record Type Details


					E4ET672BAP

Budoprutug

LIGAND->TARGET

Interaction Type:

IN-VITRO, IN-VIVO

Amount:


					LN7HYS3NX9

Nespecabtagene Autoleucel

CYTOTOXIC T-CELL->TARGET

Amount:


					0LPG0J327L

DENINTUZUMAB

LIGAND->TARGET


					H5324S1M7H

DENINTUZUMAB MAFODOTIN

CONJUGATED TOXIN->TARGET

Amount:


					BK3WC9ZP7A

Zeripatamig

INHIBITOR -> TARGET

Amount:


					4FR53SIF3A

BLINATUMOMAB

LIGAND->TARGET

Amount:


					QQA9MLH692

TAFASITAMAB

LIGAND->TARGET


					3QW12I37H1

Surovatamig

AGONIST -> TARGET

Amount:


					7K5O7P6QIU

LONCASTUXIMAB TESIRINE

CONJUGATED TOXIN->TARGET


					99C5N75ES4

EVONCABTAGENE PAZURGEDLEUCEL EXPRESSED ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR

LIGAND->TARGET

Amount:


					MRS84YT9L2

COLTUXIMAB RAVTANSINE

INHIBITOR -> TARGET


					UGA95385P3

AFM-11

LIGAND->TARGET


					DS272D3LHY

Resecabtagene Autoleucel

CYTOTOXIC T-CELL->TARGET

Amount:


					RM16A4BA8R

OBEXELIMAB

INHIBITOR -> TARGET

Comments:

Co-ligation of CD19 and FcgRIIb leads to downregulation and inhibition of B lineage cells bearing these targets.

Amount:


					74T7185BMM

INEBILIZUMAB

LIGAND->TARGET


					J545GSE96Y

DUVORTUXIZUMAB

INHIBITOR -> TARGET


					EJG3KK52YP

Rapcabtagene Autoleucel

CYTOTOXIC T-CELL->TARGET

Amount:


					W86XKJ6C6Y

TEBROCABTAGENE AUTOLEUCEL

LIGAND->TARGET


					4FR53SIF3A

BLINATUMOMAB

LIGAND->TARGET


					0LPG0J327L

DENINTUZUMAB

INHIBITOR -> TARGET


					9JHE6G6VCM

Anbalcabtagene Autoleucel

CYTOTOXIC T-CELL->TARGET

Amount:


					A4O2H9W17Y

VADACABTAGENE LERALEUCEL

IMMUNE RESPONSIVE CELLS->TARGET ANTIGEN

Structural Modifications

Modification Type	Location Site	Location Type	Residue Modified	Extent	Fragment Name	Fragment Approval
AMINO ACID SUBSTITUTION	[1_329] [1_359] [1_390] [1_420] [1_481]				TYROSINE O-PHOSPHATE	2R86C98KDX
AMINO ACID SUBSTITUTION	[1_208]			Amount:	DEXFOSFOSERINE	VI4F0K069V

Name	Property Type	Amount	Referenced Substance	Defining	Parameters	References
MOL_WEIGHT	CHEMICAL